Please login to the form below

Not currently logged in
Email:
Password:

GVAX

This page shows the latest GVAX news and features for those working in and with pharma, biotech and healthcare.

Aduro pancreatic cancer vaccine trial disappoints

Aduro pancreatic cancer vaccine trial disappoints

The immunotherapy combines CRS-207 - a drug that promotes the expression of the tumour-associated antigen mesothelin - with an immune-boosting GVAX cell line, and is Aduro's lead product candidate. ... Aduro is not giving up on the CRS-207/GVAX vaccine

Latest news

  • Pfizer's Bosulif gets conditional green light for CML in Europe Pfizer's Bosulif gets conditional green light for CML in Europe

    mechanism of action than the current crop of treatments, as well as Cephalon/Hospira's Omapro (omacetaxine), BioSante Pharma's GVAX and Deciphera's ABL inhibitor rebastinib (DCC-2036).

  • Pfizer gets US approval for leukaemia drug Bosulif

    Other competition in the coming years could emerge from the likes of Cephalon/Hospira's Omapro (omacetaxine), BioSante Pharma's GVAX and Deciphera's ABL inhibitor rebastinib (DCC-2036).

  • Combating cancer

    Vaccines such as CancerVax (Canvaxin), Genitope Corp (MyVax personalised immunotherapy), Favrille Inc (FavId), Therion (Panvac), CG 8123 (Gvax; Cell Genesys) have not been as successful, and development of these vaccines has

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics